An interventional study of Collection of vaginal secretions and Collection of the placenta and the membranes in Preterm Labor, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-20.
Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Premature Birth by Assistance Publique - Hôpitaux de Paris — 6 open to participants now, 7 under way, 2 of them phase 3. Premature Birth · Assistance Publique - Hôpitaux de Paris.
Among the 26 studies in Premature Birth by Assistance Publique - Hôpitaux de Paris, this one has the largest planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2023, is one of 12 with no phase, and was the 21st registered.
2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.
Browse Premature Birth studies →6 of the 26 studies in Premature Birth by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 6 yrs–78 mo
Assistance Publique - Hôpitaux de Paris · Sites in France
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+ · Women only
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+ · Women only
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 0 days–28 mo
By country, each count listing its studies:
Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 5 · Phase 4 2
First in 2002; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,600 is above the median of 84 across 1,670 interventional studies indexed under Premature Birth.
Median enrollment 133 across the 20 interventional studies, 253 across the 6 observational. Of the 19 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
2 of the studies in Premature Birth by Assistance Publique - Hôpitaux de Paris that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03976063Phase 3Assistance Publique - Hôpitaux de ParisTocolysis in the Management of Preterm Premature Rupture of Membranes Before 34 Weeks of Gestation | 2026-11 |
| NCT05586334Assistance Publique - Hôpitaux de ParisDevelopment and Clinical Evaluation of an Innovative Medical Device to Predict Preterm Birth (PrediMAP) | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 26 studies in Premature Birth by Assistance Publique - Hôpitaux de Paris, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to clinically validate the predictive performance (sensitivity and specificity) of the PrediMAP in-vitro diagnostic medical device to predict delivery within 7 days in the target population of women consulting obstetric emergencies for preterm labor (PTL).
Preterm delivery (birth before 37 weeks of gestation) accounts for 12% of worldwide births each year: 15 million children. It is the leading cause of infant mortality. In France, it accounts for 60,000 births per year, 10,000 of them very preterm (before 32 weeks) and at very high risk of neonatal complications and childhood sequelae Given the high risks of death and of neurodevelopmental disabilities and learning disorders among survivors, preterm birth (PTB) is a major public health problem .
Over the past 30 years, measures to prevent preterm deliveries have not proved effective, and the incidence of PTB is rising or at best stable in most developed countries, including France. Important advances have nonetheless improved the management of pregnancies at risk of PTB and of preterm children.
From 100,000 to 150,000 women a year come to maternity unit EDs for symptoms suggesting PTL. Although fewer than half will be admitted to the hospital, our team has shown that PTL is the leading reason for hospitalization among pregnant women (45,000 admissions/year) in France [4]. In the USA, PTL is also the main cause of hospitalization during pregnancy, with costs estimated at $820 million annually . This hospitalization benefits only those women who finally do give birth preterm.
The PrediMAP project's ambition is to use new markers involved in the mechanism of PTL in clinical practice - biomarkers that are the fruit of more than 10 years of basic research at the Institut Cochin. The objective is to combine their measurement with clinical and ultrasound data to construct an algorithm to predict PTB within 7 days after the test, one that medical teams can use in obstetric EDs.
The final objective is to obtain a personalized prediction of delivery within 7 days via an algorithm integrated in the IVD-MD that includes clinical and ultrasound data with these biomarker measurements.
This study is conducted in 3 phases (3 cohorts).
Objectives of Cohort 1 (Development) :
2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.
This study's planned enrollment of 3,600 is above the median of 84 across 1,670 interventional studies indexed under Premature Birth.
Browse Premature Birth studies →Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
Compared within Premature Birth, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Obstetric Labor, Premature. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For a suspicion of PTL defined by :
Exclusion Criteria
In all women included: Vaginal secretion sampling at the time of the obstetrical emergency consultation.
In cohort 1, for 30 patients at the Port Royal Maternity Hospital, the placenta and membranes will be collected after delivery
In cohort 3, the EPDS questionnaire will be administered to all participants after the consultation in the emergency department.
Delivery occurence 7 days after inclusion
Time frame: Cohort 1 : assessed 15-21 days after inclusion of each patient. Cohort 3: assessed after end of follow-up (5.5 months).
delivery occurrence 14 days after consultation
Time frame: assessed after end of follow-up (5.5 months)
delivery <32 weeks of gestation, <34 weeks and <37 weeks
Gestational age at delivery, in 4 categories.
Time frame: assessed after end of follow-up (5.5 months)
neonatal mortality;
Time frame: assessed after end of follow-up (5.5 months)
severe neonatal morbidity
Defined by one or more of the following : * Bronchopumonary dyplasia * Necrotizing enterocolitis stage 2 or 3 * Intraventricular haemorrhage stage 3-4 * Periventricular leukomalacia * Retinopathy of prematurity stage \>3
Time frame: assessed after end of follow-up (5.5 months)
EPDS score at inclusion and after delivery
Time frame: assessed after end of follow-up (5.5 months)
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2023 (actual). Primary completion is estimated for Jun 2027, 48 months after the start.
Of 746 non-industry interventional studies with no phase under Premature Birth, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 48 months is above that.
Counting every sponsor, half of 764 studies reached it within 24 months; a quarter within 12 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →